Home › Liver Cancer (Hepatocellular Carcinoma) › NCT03894917

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Characterizing Disease Biology, Treatment Patterns and Toxicity in Older Adults With Advanced Hepatocellular Carcinoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma.
* Age 18 years and older.
* Patients with advanced, unresectable HCC as determined by the treating physician.

Exclusion Criteria:

* Patients with resectable HCC who are still candidates for locoregional therapy
* Patients receiving prior systemic or locoregional therapy

About the study

This is an observational, prospective cohort study that will recruit a diverse sample of 84 participants with newly diagnosed with unresectable, advanced hepatocellular carcinoma (HCC) at the UT Health Cancer Center in San Antonio. This study uses geriatric assessment tools with participants 65 years and older and collects adverse events and exploratory markers of aging for all participants.

What is being tested

• Comprehensive Geriatric Assessment (CGA) (other)

Sponsor: The University of Texas Health Science Center at San Antonio · Participants: 84 · Started: Sep 13, 2019

Contact the study team

• Maggie Tomasini, MPH · Phone: 210-450-0507

Official record on ClinicalTrials.gov — NCT03894917

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.